Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome

Due to the absence of hormone receptor (<i>both estrogen receptors and progesterone receptors</i>) along with human epidermal growth factor receptor 2 (HER-2) amplification, the treatment of triple-negative breast cancer (TNBC) cannot benefit from endocrine or anti-HER-2 therapy. For a l...

Full description

Bibliographic Details
Main Authors: Liying Li, Fan Zhang, Zhenyu Liu, Zhimin Fan
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
triple-negative breast cancer
immunotherapy
immune checkpoint
tumor immune microenvironment
clinical trials
Online Access:https://www.mdpi.com/2072-6694/15/1/321

Internet

https://www.mdpi.com/2072-6694/15/1/321

Similar Items